2
|
Chung MY, Lu YC, Cheng NC, Soong BW. A novel autosomal dominant spinocerebellar ataxia (SCA22) linked to chromosome 1p21-q23. Brain 2003; 126:1293-9. [PMID: 12764052 DOI: 10.1093/brain/awg130] [Citation(s) in RCA: 72] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The autosomal dominant cerebellar ataxias (ADCA) are a clinically, pathologically and genetically heterogeneous group of disorders. Ten responsible genes have been identified for spinocerebellar ataxia types SCA1, SCA2, SCA3, SCA6, SCA7, SCA8, SCA10, SCA12 and SCA17, and dentatorubral pallidoluysian atrophy (DRPLA). The mutation is caused by an expansion of a CAG, CTG or ATTCT repeat sequence of these genes. Six additional loci, SCA4, SCA5, SCA11, SCA13, SCA14 and SCA16 have also been mapped. The growing heterogeneity of the autosomal dominant forms of these diseases shows that the genetic aetiologies of at least 20% of ADCA have yet to be elucidated. We ascertained and clinically characterized a four-generation Chinese pedigree segregating an autosomal dominant phenotype for cerebellar ataxia. Direct mutation analysis, linkage analysis for all known SCA loci and a genome-wide linkage study were performed. Direct mutation analysis excluded SCA1, 2, 3, 6, 7, 8, 10, 12, 17 and DRPLA, and genetic linkage analysis excluded SCA4, 5, 11, 13, 14 and 16. The genome-wide linkage study suggested linkage to a locus on chromosome 1p21-q23, with the highest two-point LOD score at D1S1167 (Zmax = 3.46 at theta = 0.00). Multipoint analysis and haplotype reconstruction traced this novel SCA locus (SCA22) to a 43.7-cM interval flanked by D1S206 and D1S2878 (Zmax = 3.78 under four liability classes, and 2.67 using affected-only method). The age at onset ranged from 10 to 46 years. All affected members had gait ataxia with variable features of dysarthria and hyporeflexia. Head MRI showed homogeneous atrophy of the cerebellum without involvement of the brainstem. In six parent-child pairs, median onset occurred 10 years earlier in offspring than in their parents, suggesting anticipation. This family is distinct from other families with SCA and is characterized by a slowly progressive, pure cerebellar ataxia.
Collapse
Affiliation(s)
- Ming-Yi Chung
- Department of Medical Research and Education, Taipei Veterans General Hospital, and Genome Research Centre, National Yang-Ming University, Taiwan
| | | | | | | |
Collapse
|
3
|
Vincent JB, Paterson AD, Strong E, Petronis A, Kennedy JL. The unstable trinucleotide repeat story of major psychosis. AMERICAN JOURNAL OF MEDICAL GENETICS 2003; 97:77-97. [PMID: 10813808 DOI: 10.1002/(sici)1096-8628(200021)97:1<77::aid-ajmg11>3.0.co;2-3] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
New hopes for cloning susceptibility genes for schizophrenia and bipolar affective disorder followed the discovery of a novel type of DNA mutation, namely unstable DNA. One class of unstable DNA, trinucleotide repeat expansion, is the causal mutation in myotonic dystrophy, fragile X mental retardation, Huntington disease and a number of other rare Mendelian neurological disorders. This finding has led researchers in psychiatric genetics to search for unstable DNA sites as susceptibility factors for schizophrenia and bipolar affective disorder. Increased severity and decreased age at onset of disease in successive generations, known as genetic anticipation, was reported for undifferentiated psychiatric diseases and for myotonic dystrophy early in the twentieth century, but was initially dismissed as the consequence of ascertainment bias. Because unstable DNA was demonstrated to be a molecular substrate for genetic anticipation in the majority of trinucleotide repeat diseases including myotonic dystrophy, many recent studies looking for genetic anticipation have been performed for schizophrenia and bipolar affective disorder with surprisingly consistent positive results. These studies are reviewed, with particular emphasis placed on relevant sampling and statistical considerations, and concerns are raised regarding the interpretation of such studies. In parallel, molecular genetic investigations looking for evidence of trinucleotide repeat expansion in both schizophrenia and bipolar disorder are reviewed. Initial studies of genome-wide trinucleotide repeats using the repeat expansion detection technique suggested possible association of large CAG/CTG repeat tracts with schizophrenia and bipolar affective disorder. More recently, three loci have been identified that contain large, unstable CAG/CTG repeats that occur frequently in the population and seem to account for the majority of large products identified using the repeat expansion detection method. These repeats localize to an intron in transcription factor gene SEF2-1B at 18q21, a site named ERDA1 on 17q21 with no associated coding region, and the 3' end of a gene on 13q21, SCA8, that is believed to be responsible for a form of spinocerebellar ataxia. At present no strong evidence exists that large repeat alleles at either SEF2-1B or ERDA1 are involved in the etiology of schizophrenia or bipolar disorder. Preliminary evidence suggests that large repeat alleles at SCA8 that are non-penetrant for ataxia may be a susceptibility factor for major psychosis. A fourth, but much more infrequently unstable CAG/CTG repeat has been identified within the 5' untranslated region of the gene, MAB21L1, on 13q13. A fifth CAG/CTG repeat locus has been identified within the coding region of an ion transporter, KCNN3 (hSKCa3), on 1q21. Although neither large alleles nor instability have been observed at KCNN3, this repeat locus has been extensively analyzed in association and family studies of major psychosis, with conflicting findings. Studies of polyglutamine containing genes in major psychosis have also shown some intriguing results. These findings, reviewed here, suggest that, although a major role for unstable trinucleotides in psychosis is unlikely, involvement at a more modest level in a minority of cases cannot be excluded, and warrants further investigation.
Collapse
Affiliation(s)
- J B Vincent
- Department of Genetics at the Hospital for Sick Children, Toronto, Canada
| | | | | | | | | |
Collapse
|
5
|
Herman-Bert A, Stevanin G, Netter JC, Rascol O, Brassat D, Calvas P, Camuzat A, Yuan QP, Schalling M, Dürr A, Brice A. Mapping of spinocerebellar ataxia 13 to chromosome 19q13.3-q13.4 in a family with autosomal dominant cerebellar ataxia and mental retardation. Am J Hum Genet 2000; 67:229-35. [PMID: 10820125 PMCID: PMC1287081 DOI: 10.1086/302958] [Citation(s) in RCA: 115] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2000] [Accepted: 03/12/2000] [Indexed: 11/03/2022] Open
Abstract
We examined a large French family with autosomal dominant cerebellar ataxia (ADCA) that was excluded from all previously identified spinocerebellar ataxia genes and loci. The patients-seven women and a 4-year-old boy-exhibited slowly progressive childhood-onset cerebellar gait ataxia associated with cerebellar dysarthria, moderate mental retardation (IQ 62-76), and mild developmental delays in motor acquisition. Nystagmus and pyramidal signs were also observed in some cases. This unique association of clinical features clearly distinguishes this new entity from other previously described ADCA. Cerebral magnetic-resonance imaging showed moderate cerebellar and pontine atrophy in two patients. We performed a genomewide search and found significant evidence for linkage to chromosome 19q13.3-q13.4, in an approximately 8-cM interval between markers D19S219 and D19S553.
Collapse
Affiliation(s)
- Alexandra Herman-Bert
- INSERM U289, Hôpital de la Salpêtrière, and Consultation de Génétique Médicale, Hôpital de la Salpêtrière, Paris; Service de Néonatologie, Centre Hospitalier Intercommunal de Tarbes, Tarbes, France; Service de Pharmacologie Clinique, Faculté de Médecine, Fédération de Neurologie, Hôpital Purpan, and Consultation de Génétique Médicale, Hôpital Purpan, Toulouse, France; and Neurogenetics Unit, Department of Molecular Medicine, Karolinska Hospital, Stockholm
| | - Giovanni Stevanin
- INSERM U289, Hôpital de la Salpêtrière, and Consultation de Génétique Médicale, Hôpital de la Salpêtrière, Paris; Service de Néonatologie, Centre Hospitalier Intercommunal de Tarbes, Tarbes, France; Service de Pharmacologie Clinique, Faculté de Médecine, Fédération de Neurologie, Hôpital Purpan, and Consultation de Génétique Médicale, Hôpital Purpan, Toulouse, France; and Neurogenetics Unit, Department of Molecular Medicine, Karolinska Hospital, Stockholm
| | - Jean-Claude Netter
- INSERM U289, Hôpital de la Salpêtrière, and Consultation de Génétique Médicale, Hôpital de la Salpêtrière, Paris; Service de Néonatologie, Centre Hospitalier Intercommunal de Tarbes, Tarbes, France; Service de Pharmacologie Clinique, Faculté de Médecine, Fédération de Neurologie, Hôpital Purpan, and Consultation de Génétique Médicale, Hôpital Purpan, Toulouse, France; and Neurogenetics Unit, Department of Molecular Medicine, Karolinska Hospital, Stockholm
| | - Olivier Rascol
- INSERM U289, Hôpital de la Salpêtrière, and Consultation de Génétique Médicale, Hôpital de la Salpêtrière, Paris; Service de Néonatologie, Centre Hospitalier Intercommunal de Tarbes, Tarbes, France; Service de Pharmacologie Clinique, Faculté de Médecine, Fédération de Neurologie, Hôpital Purpan, and Consultation de Génétique Médicale, Hôpital Purpan, Toulouse, France; and Neurogenetics Unit, Department of Molecular Medicine, Karolinska Hospital, Stockholm
| | - David Brassat
- INSERM U289, Hôpital de la Salpêtrière, and Consultation de Génétique Médicale, Hôpital de la Salpêtrière, Paris; Service de Néonatologie, Centre Hospitalier Intercommunal de Tarbes, Tarbes, France; Service de Pharmacologie Clinique, Faculté de Médecine, Fédération de Neurologie, Hôpital Purpan, and Consultation de Génétique Médicale, Hôpital Purpan, Toulouse, France; and Neurogenetics Unit, Department of Molecular Medicine, Karolinska Hospital, Stockholm
| | - Patrick Calvas
- INSERM U289, Hôpital de la Salpêtrière, and Consultation de Génétique Médicale, Hôpital de la Salpêtrière, Paris; Service de Néonatologie, Centre Hospitalier Intercommunal de Tarbes, Tarbes, France; Service de Pharmacologie Clinique, Faculté de Médecine, Fédération de Neurologie, Hôpital Purpan, and Consultation de Génétique Médicale, Hôpital Purpan, Toulouse, France; and Neurogenetics Unit, Department of Molecular Medicine, Karolinska Hospital, Stockholm
| | - Agnès Camuzat
- INSERM U289, Hôpital de la Salpêtrière, and Consultation de Génétique Médicale, Hôpital de la Salpêtrière, Paris; Service de Néonatologie, Centre Hospitalier Intercommunal de Tarbes, Tarbes, France; Service de Pharmacologie Clinique, Faculté de Médecine, Fédération de Neurologie, Hôpital Purpan, and Consultation de Génétique Médicale, Hôpital Purpan, Toulouse, France; and Neurogenetics Unit, Department of Molecular Medicine, Karolinska Hospital, Stockholm
| | - Qiu-ping Yuan
- INSERM U289, Hôpital de la Salpêtrière, and Consultation de Génétique Médicale, Hôpital de la Salpêtrière, Paris; Service de Néonatologie, Centre Hospitalier Intercommunal de Tarbes, Tarbes, France; Service de Pharmacologie Clinique, Faculté de Médecine, Fédération de Neurologie, Hôpital Purpan, and Consultation de Génétique Médicale, Hôpital Purpan, Toulouse, France; and Neurogenetics Unit, Department of Molecular Medicine, Karolinska Hospital, Stockholm
| | - Martin Schalling
- INSERM U289, Hôpital de la Salpêtrière, and Consultation de Génétique Médicale, Hôpital de la Salpêtrière, Paris; Service de Néonatologie, Centre Hospitalier Intercommunal de Tarbes, Tarbes, France; Service de Pharmacologie Clinique, Faculté de Médecine, Fédération de Neurologie, Hôpital Purpan, and Consultation de Génétique Médicale, Hôpital Purpan, Toulouse, France; and Neurogenetics Unit, Department of Molecular Medicine, Karolinska Hospital, Stockholm
| | - Alexandra Dürr
- INSERM U289, Hôpital de la Salpêtrière, and Consultation de Génétique Médicale, Hôpital de la Salpêtrière, Paris; Service de Néonatologie, Centre Hospitalier Intercommunal de Tarbes, Tarbes, France; Service de Pharmacologie Clinique, Faculté de Médecine, Fédération de Neurologie, Hôpital Purpan, and Consultation de Génétique Médicale, Hôpital Purpan, Toulouse, France; and Neurogenetics Unit, Department of Molecular Medicine, Karolinska Hospital, Stockholm
| | - Alexis Brice
- INSERM U289, Hôpital de la Salpêtrière, and Consultation de Génétique Médicale, Hôpital de la Salpêtrière, Paris; Service de Néonatologie, Centre Hospitalier Intercommunal de Tarbes, Tarbes, France; Service de Pharmacologie Clinique, Faculté de Médecine, Fédération de Neurologie, Hôpital Purpan, and Consultation de Génétique Médicale, Hôpital Purpan, Toulouse, France; and Neurogenetics Unit, Department of Molecular Medicine, Karolinska Hospital, Stockholm
| |
Collapse
|